Evidence that small molecule enhancement of β-hexosaminidase activity corrects the behavioral phenotype in Dutch APPE693Q mice through reduction of ganglioside-bound Aβ

Molecular Psychiatry

Volumn 20, Issue 1, 2015, Pages 109-117

  Knight, E M ^a   Williams, H N ^b   Stevens, A C ^c   Kim, S H ^a   Kottwitz, J C ^a   Morant, A D ^a   Steele, J W ^c   Klein, W L ^d   Yanagisawa, K ^e   Boyd, R E ^b   Lockhart, D J ^c   Sjoberg, E R ^c   Ehrlich, M E ^a   Wustman, B A ^c   Gandy, S ^a,f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Amicus Therapeutics   (United States)

^c OrPhi Therapeutics   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BETA N ACETYLHEXOSAMINIDASE; GANGLIOSIDE; GANGLIOSIDE GM2; OT 1001; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; NEUROLEPTIC AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG SELECTIVITY; ENZYME ACTIVITY; IN VITRO STUDY; LEARNING; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PERIRHINAL CORTEX; PHENOTYPE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUBICULUM; TASK PERFORMANCE; ALZHEIMER DISEASE; ANIMAL; BLOOD TESTIS BARRIER; C57BL MOUSE; CELL CULTURE; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; FIBROBLAST; GENETICS; HUMAN; MAZE TEST; METABOLISM; MUTATION; RECOGNITION; TIME;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIPSYCHOTIC AGENTS; BETA-N-ACETYLHEXOSAMINIDASES; BLOOD-TESTIS BARRIER; CELLS, CULTURED; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; GANGLIOSIDES; HUMANS; MAZE LEARNING; MICE; MICE, INBRED C57BL; MUTATION; RECOGNITION (PSYCHOLOGY); TIME FACTORS;

EID: 84922243384     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.135     Document Type: Article

References (50)

1. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang M, Rosado L, Orbe Reilly M et al. Cognitive performance of GBA mutation carriers with early-onset PD: the COREPD study. Neurology 2012; 78: 1434-1440.
2. Daniele A, Albanese A. Early visual memory deficits: a neuropsychological marker of GBA mutations in PD? Neurology 2012; 78: 1372-1373.
3. Lee H, Lee JK, Bae YC, Yang SH, Okino N, Schuchman EH et al. Inhibition of GM3 synthase attenuates neuropathology of niemann-pick disease type C by affecting sphingolipid metabolism. Mol Cells 2014; 37: 161-171.
4. Zervas M, Somers KL, Thrall MA, Walkley SU. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol 2001; 11: 1283-1287.
5. Malnar M, Hecimovic S, Mattsson N, Zetterberg H. Bidirectional links between Alzheimer's disease and Niemann-Pick type C disease. Neurobiol Dis advance online publication, 4 June 2014; doi:10.1016/j.nbd.2014.05.033 (e-pub ahead of print).
6. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361: 1651-1661.
7. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011; 146: 37-52.
8. Yap TL, Velayati A, Sidransky E, Lee JC. Membrane-bound alpha-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol Genet Metab 2013; 108: 56-64.
9. Yanagisawa K. Role of gangliosides in Alzheimer's disease. Biochim Biophys Acta 2007; 1768: 1943-1951.
10. Mutoh T, Hirabayashi Y, Mihara T, Ueda M, Koga H, Ueda A et al. Role of glycosphingolipids and therapeutic perspectives on Alzheimer's disease. CNS Neurol Disord Drug Targets 2006; 5: 375-380.
11. Hayashi H, Kimura N, Yamaguchi H, Hasegawa K, Yokoseki T, Shibata M et al. A seed for Alzheimer amyloid in the brain. J Neurosci 2004; 24: 4894-4902.
12. Kracun I, Rosner H, Drnovsek V, Heffer-Lauc M, Cosovic C, Lauc G. Human brain gangliosides in development, aging and disease. Int J Dev Biol 1991; 35: 289-295.
13. Brooksbank BW, McGovern J. Gangliosides in the brain in adult Down's syndrome and Alzheimer's disease. Mol Chem Neuropathol 1989; 11: 143-156.
14. Matsuzaki K. Physicochemical interactions of amyloid [beta]-peptide with lipid bilayers. Biochim Biophys Acta 2007; 1768: 1935-1942.
15. Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta 2010; 1801: 878-886.
16. Gylys KH, Fein JA, Yang F,Miller CA, Cole GM. Increased cholesterol in A[beta]-positive nerve terminals from Alzheimer's disease cortex. Neurobiol Aging 2007; 28: 8-17.
17. Molander-Melin M, Blennow K, Bogdanovic N, Dellheden B, Mansson JE, Fredman P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem 2005; 92: 171-182.
18. Yanagisawa K, Odaka A, Suzuki N, Ihara Y. GM1 ganglioside-bound amyloid betaprotein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat Med 1995; 1: 1062-1066.
19. Yanagisawa K, McLaurin J, Michikawa M, Chakrabartty A, Ihara Y. Amyloid [beta]-protein (A[beta]) associated with lipid molecules: immunoreactivity distinct from that of soluble A[beta]. FEBS Lett 1997; 420: 43-46.
20. Yanagisawa K, Ihara Y. GM1 ganglioside-bound amyloid beta-protein in Alzheimer's disease brain. Neurobiol Aging 1998; 19: S65-S67.
21. Yanagisawa K. Role of gangliosides in Alzheimer's disease. Biochim Biophys Acta 2007; 1768: 1943-1951.
22. Yamamoto N, Hirabayashi Y, Amari M, Yamaguchi H, Romanov G, Van Nostrand WE et al. Assembly of hereditary amyloid beta-protein variants in the presence of favorable gangliosides. FEBS Lett 2005; 579: 2185-2190.
23. Selkoe DJ. Alzheimer's amyloid of another flavour. Nat Med 1995; 1: 998-999.
24. Yamamoto N, Van Nostrand WE, Yanagisawa K. Further evidence of local ganglioside-dependent amyloid beta-protein assembly in brain. Neuroreport 2006; 17: 1735-1737.
25. Mahuran DJ. Biochemical consequences of mutations causing the GM2 gangliosidoses. Biochim Biophys Acta 1999; 1455: 105-138.
26. Keilani S, Lun Y, Stevens AC, Williams HN, Sjoberg ER, Khanna R et al. Lysosomal dysfunction in a mouse model of Sandhoff disease leads to accumulation of ganglioside-bound amyloid-beta peptide. J Neurosci 2012; 32: 5223-5236.
27. Tamboli IY, Hampel H, Tien NT, Tolksdorf K, Breiden B, Mathews PM et al. Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Abeta generation. J Neurosci 2011; 31: 1837-1849.
28. Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC et al. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol 2010; 68: 220-230.
29. Boyd RE, Lee G, Rybczynski P, Benjamin ER, Khanna R, Wustman BA et al. Pharmacological chaperones as therapeutics for lysosomal storage diseases. J Medi Chem 2013; 56: 2705-2725.
30. Tropak MB, Reid SP, Guiral M, Withers SG, Mahuran D. Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J Biol Chem 2004; 279: 13478-13487.
31. Wustman BA, Boudes P, Lockhart DJ. Stabilizing mutant proteins with small molecules: an example from Fabry Disease. Pediatr Pulm 2012; 47: 114-116.
32. Osher E, Fattal-Valevski A, Sagie L, Urshanski N, Amir-Levi Y, Katzburg S et al. Pyrimethamine increases beta-hexosaminidase A activity in patients with Late Onset Tay Sachs. Mol Genet Metab 2011; 102: 356-363.
33. Clarke JT, Mahuran DJ, Sathe S, Kolodny EH, Rigat BA, Raiman JA et al. An openlabel Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Mol Genet Metab 2011; 102: 6-12.
34. Amicus Therapeutics Announces Positive 12-and 24-Month Data from Phase 3 Fabry Monotherapy Study 011 (Press release). Amicus Therapeutics 2014.
35. Maegawa GH, Tropak M, Buttner J, Stockley T, Kok F, Clarke JT et al. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J Biol Chem 2007; 282: 9150-9161.
36. Mark BL, Mahuran DJ, Cherney MM, Zhao D, Knapp S, James MN. Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease. J Mol Biol 2003; 327: 1093-1109.
37. Bateman KS, Cherney MM, Mahuran DJ, Tropak M, James MN. Crystal structure of beta-hexosaminidase B in complex with pyrimethamine, a potential pharmacological chaperone. J Med Chem 2011; 54: 1421-1429.
38. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000; 404: 770-774.
39. Petaja-Repo UE, Hogue M, Laperriere A, Bhalla S, Walker P, Bouvier M. Newly synthesized human delta opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome. J Biol Chem 2001; 276: 4416-4423.
40. Steet RA, Chung S, Wustman B, Powe A, Do H, Kornfeld SA. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci USA 2006; 103: 13813-13818.
41. Bernier V, Bichet DG, Bouvier M. Pharmacological chaperone action on G-proteincoupled receptors. Curr Opin Pharmacol 2004; 4: 528-533.
42. Chang EH, Huerta PT. Neurophysiological correlates of object recognition in the dorsal subiculum. Front Behav Neurosci 2012; 6: 46.
43. Utsumi M, Yamaguchi Y, Sasakawa H, Yamamoto N, Yanagisawa K, Kato K. Up-and-down topological mode of amyloid beta-peptide lying on hydrophilic/hydrophobic interface of ganglioside clusters. Glycoconj J 2009; 26: 999-1006.
44. Yagi-Utsumi M, Matsuo K, Yanagisawa K, Gekko K, Kato K. Spectroscopic characterization of intermolecular interaction of amyloid beta promoted on GM1 micelles. Int J Alzheimer's Dis 2010; 2011: 925073.
45. Kakio A, Nishimoto SI, Yanagisawa K, Kozutsumi Y, Matsuzaki K. Cholesteroldependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 2001; 276: 24985-24990.
46. Manna M, Mukhopadhyay C. Binding, conformational transition and dimerization of amyloid-beta peptide on GM1-containing ternary membrane: insights from molecular dynamics simulation. PLoS One 2013; 8: e71308.
47. Fantini J, Yahi N, Garmy N. Cholesterol accelerates the binding of Alzheimer's beta-amyloid peptide to ganglioside GM1 through a universal hydrogenbond-dependent sterol tuning of glycolipid conformation. Front Physiol 2013; 4: 120.
48. Hong S, Ostaszewski BL, Yang T, O'Malley TT, Jin M, Yanagisawa K et al. Soluble Abeta oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron 2014; 82: 308-319.
49. Ariga T, Kobayashi K, Hasegawa A, Kiso M, Ishida H, Miyatake T. Characterization of high-affinity binding between gangliosides and amyloid beta-protein. Arch Biochem Biophys 2001; 388: 225-230.
50. Yamamoto N, Yokoseki T, Shibata M, Yamaguchi H, Yanagisawa K. Suppression of A[beta] deposition in brain by peripheral administration of Fab fragments of antiseed antibody. Biochem Biophys Res Commun 2005; 335: 45-47.